Gold+
| Address | 98, Huam-ro, Jung-gu, Seoul, Republic of Korea | ||
|---|---|---|---|
| Telephone | +82-2-3459-2627 | Fax | none |
| Website | www.lilly.co.kr | kim_jihee@lilly.com | |
Lilly was founded in 1876 by Colonel Eli Lilly, a man committed to creating high-quality medicines that met real needs in an era of unreliable elixirs peddled by questionable characters. His charge to the generations of employees who have followed was this: "Take what you find here and make it better and better." More than 145 years later, we remain committed to his vision through every aspect of our business and the people we serve starting with those who take our medicines, and extending to health care professionals, employees and the communities in which we live. The purpose of Lilly is that Lilly unites caring with discovery to create medicines that make life better for people around the world. Three long-established core values (Integrity, Excellence, Respect for People) guide Lilly in all that we do as a company.
Verzenio is a targeted treatment, known as a CDK4 & 6 inhibitor, used to treat HR+/HER2- (hormone receptor positive/human epidermal growth factor receptor 2-negative) metastatic breast cancer*. Verzenio is the first and the only CDK 4&6 inhibitor that can be taken every day without break and showed significant overall survival(median) gain regardless of menopausal status in combination with fulvestrant for patients whose disease has progressed after endocrine therapy (as of Month Year). (* initial endocrine based therapy: in combination with an aromatase inhibitor for the treatment of postmenopausal women/ women with disease progression following endocrine therapy: in combination with fulvestrant) For specific information of Verzenio (including specific indication), please refer to Korean approved label. https://www.lilly.co.kr/our-medicines/verzenio
Cyramza is approved for the treatment of patients with advanced or metastatic gastric cancer, metastatic NSCLC, metastatic colorectal cancer and AFP-High (≥400ng/mL) Hepatocellular Carcinoma. Ramuricumab is a human receptor-targeted monoclonal antibody specifically binds VEGF Receptor 2 and blocks binding of VEGF-A, VEGF-C and VEGF-D. For specific information of Cyramza (including specific indication), please refer to Korean approved label. https://www.lilly.co.kr/our-medicines/cyramza
